Last edition
News about "Bezuclastinib "
Cogent Biosciences Submits NDA for Bezuclastinib in Non Advanced Systemic Mastocytosis
Cogent Biosciences has submitted a New Drug Application to the US FDA for bezuclastinib in non-advanced systemic mastocytosis, supported by positive results from the SUMMIT pivotal trial and following its Breakthrough Therapy Designation for patients with smouldering systemic mastocytosis and previously treated NonAdvSM.
Bezuclastinib | 31/12/2025 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members